Gorham–Stout disease started with recurrent bilateral exudative pleuritis: case description and literature review

Abstract

Gorham–Stout disease is an extremely rare skeletal disorder of unknown etiology manifested by multiple foci of osteolysis (“vanishing bone disease”) and lymphangiomatosis. Osteolysis can occur in any part of the skeleton (skull, facial skeleton, ribs, clavicula, spine, pelvic bones, bones of the upper and lower extremities). Approximately half of the patients develop pleural effusion, accompanied by respiratory abnormalities. We describe a case of Gorham-Stout disease with recurrent bilateral exudative pleuritis as a first and most prominent sign, while the bone lesions at the vertebral bodies, ribs and sternum proceeded without active complaints and were an accidental finding during chest computer tomography. Timely diagnosis of the disease depends on the awareness of doctors of various specialties and careful reading of imaging results.

Keywords

Gorham–Stout / osteolysis / pleuritic / sirolimus

References

[1] Gorham LW, Wright AW, Shultz HH, et al. Disappearing bones: a rare form of massive osteolysis; report of two cases, one with autopsy findings. Am J Med. 1954;17:674–682. doi: 10.1016/0002-9343(54)90027-3

[2] Gorham L.W., Wright A.W., Shultz H.H., et al. Disappearing bones: a rare form of massive osteolysis; report of two cases, one with autopsy findings // Am J Med. 1954. Vol. 17. P. 674–682. doi: 10.1016/0002-9343(54)90027-3

[3] Gorham LW, Stout AP. Massive osteolysis (acute spontaneous absorption of bone, phantom bone, disappearing bone); its relation to hemangiomatosis. J Bone Joint Surg Am. 1955;37-A(5):985–1004.

[4] Gorham L.W., Stout A.P. Massive osteolysis (acute spontaneous absorption of bone, phantom bone, disappearing bone); its relation to hemangiomatosis // J Bone Joint Surg Am. 1955. Vol. 37-A, N. 5. P. 985–1004.

[5] Angelini A, Mosele N, Pagliarini E, Ruggieri P. Current concepts from diagnosis to management in Gorham–Stout disease: a systematic narrative review of about 350 cases. EFORT Open Rev. 2022;7(1):35–48. doi: 10.1530/EOR-21-0083

[6] Angelini A., Mosele N., Pagliarini E., Ruggieri P. Current concepts from diagnosis to management in Gorham–Stout disease: a systematic narrative review of about 350 cases // EFORT Open Rev. 2022. Vol. 7, N. 1. P. 35–48. doi: 10.1530/EOR-21-0083

[7] Otteva EhN, Kocherova TYu, Shepichev EV. Massive osteolysis – Gorham–Stout syndrome. Osteoporosis and Bone Diseases. 2011;14(1):27–32. EDN: OHKRTR doi: 10.14341/osteo2011127-32

[8] Оттева Э.Н., Кочерова Т.Ю., Шепичев Е.В. Массивный остеолизис – синдром Горхэма – Стоута // Остеопороз и остеопатии. 2011. Т. 14, № 1. С. 27–32. EDN: OHKRTR doi: 10.14341/osteo2011127-32

[9] Nisichenko OA, Bondarenko VP, Minulin IR, et al. Rehabilitation features of patients with Gorham–Stout syndrome. Pediatric Bulletin of the South Ural. 2023;(1):103–111. EDN: AHDSEF doi: 10.34710/Chel.2023.32.48.011

[10] Нисиченко О.А., Бондаренко В.П., Минулин И.Р., и др. Особенности реабилитации пациентов с синдромом Горхэма – Стоута // Педиатрический вестник Южного Урала. 2023. № 1. С. 103–111. EDN: AHDSEF doi: 10.34710/Chel.2023.32.48.011

[11] Domracheva AM, Fomina-Chertousova NA, Sozaeva DI. Development of idiopathic intracranial hypertension on the background of zoledronic acid therapy in Gorham–Stoat syndrome. Medical Herald of the South of Russia. 2023;14(3):46–50. EDN: ZEIARL doi: 10.21886/2219-8075-2023-14-3-46-50

[12] Домрачева А.М., Фомина-Чертоусова Н.А., Созаева Д.И. Развитие идиопатической внутричерепной гипертензии на фоне терапии золедроновой кислотой при синдроме Горхэма – Стоута // Медицинский вестник Юга России. 2023. Т. 14, № 3. С. 46–50. EDN: ZEIARL doi: 10.21886/2219-8075-2023-14-3-46-50

[13] Kryukov AI, Karpova EP, Toropchina LV, et al. Unilateral subjective tinnitus “vanishing bone” disease (Goram–Stout syndrome). Vestn Otorinolaringol. 2022;87(5):92–98. EDN: TWXBWW doi: 10.17116/otorino20228705192

[14] Крюков А.И., Карпова Е.П., Торопчина Л.В., и др. Односторонний субъективный шум при болезни «исчезающей кости» (синдром Горхема – Стоута) // Вестник оториноларингологии. 2022. Т. 87, № 5. С. 92–98. EDN: TWXBWW doi: 10.17116/otorino20228705192

[15] Hardegger F, Simpson LA, Segmueller G. The syndrome of idiopathic osteolysis. Classification, review, and case report. J Bone Joint Surg Br. 1985;67(1):88–93. doi: 10.1302/0301-620X.67B1.3968152

[16] Hardegger F., Simpson L.A., Segmueller G. The syndrome of idiopathic osteolysis. Classification, review, and case report // J Bone Joint Surg Br. 1985. Vol. 67, N. 1. P. 88–93. doi: 10.1302/0301-620X.67B1.3968152

[17] ISSVA Classification of Vascular Anomalies. 2018 [Internet]. International Society for the Study of Vascular Anomalies. Available from: issva.org/classification. Accessed: 03 Jan 2023.

[18] ISSVA Classification of Vascular Anomalies. 2018 [Электронный ресурс] // International Society for the Study of Vascular Anomalies. Режим доступа: issva.org/classification. Дата обращения: 03.01.2023.

[19] Ozeki M, Fukao T. Generalized lymphatic anomaly and gorham-stout disease: overview and recent insights. Adv Wound Care (New Rochelle). 2019;8(6):230–245. doi: 10.1089/wound.2018.0850

[20] Ozeki M., Fukao T. Generalized lymphatic anomaly and gorham-stout disease: overview and recent insights // Adv Wound Care (New Rochelle). 2019. Vol. 8, N. 6. P. 230–245. doi: 10.1089/wound.2018.0850

[21] Nagy JA, Vasile E, Feng D, et al. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med. 2002;196(11):1497–1506. doi: 10.1084/jem.20021244

[22] Nagy J.A., Vasile E., Feng D., et al. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis // J Exp Med. 2002. Vol. 196, No. 11. P. 1497–1506. doi: 10.1084/jem.20021244

[23] Lohela M, Bry M, Tammela T, Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol. 2009;21(2):154–165. doi: 10.1016/j.ceb.2008.12.012

[24] Lohela M., Bry M., Tammela T., Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis // Curr Opin Cell Biol. 2009. Vol. 21, N. 2. P. 154–165. doi: 10.1016/j.ceb.2008.12.012

[25] Hirayama T, Sabokbar A, Itonaga I, et al. Cellular and humoral mechanisms of osteoclast formation and bone resorption in Gorham-Stout disease. J Pathol. 2001;195(5):624–630. doi: 10.1002/path.989

[26] Hirayama T., Sabokbar A., Itonaga I., et al. Cellular and humoral mechanisms of osteoclast formation and bone resorption in Gorham-Stout disease // J Pathol. 2001. Vol. 195, No. 5. P. 624–630. doi: 10.1002/path.989

[27] Liu S, Zhou X, Song A, et al. Successful treatment of Gorham-Stout syndrome in the spine by vertebroplasty with cement augmentation: A case report and literature review. Medicine (Baltimore). 2018;97(29):e11555. doi: 10.1097/MD.0000000000011555

[28] Liu S., Zhou X., Song A., et al. Successful treatment of Gorham-Stout syndrome in the spine by vertebroplasty with cement augmentation: a case report and literature review // Medicine (Baltimore). 2018. Vol. 97, N. 29. P. e11555. doi: 10.1097/MD.0000000000011555

[29] Heffez L, Doku HC, Carter BL, Feeney JE. Perspectives on massive osteolysis. Report of a case and review of the literature. Oral Surg Oral Med Oral Pathol. 1983;55(4):331–343. doi: 10.1016/0030-4220(83)90185-8

[30] Heffez L., Doku H.C., Carter B.L., Feeney J.E. Perspectives on massive osteolysis. Report of a case and review of the literature // Oral Surg Oral Med Oral Pathol. 1983. Vol. 55, N. 4. P. 331–343. doi: 10.1016/0030-4220(83)90185-8

[31] Di H, Zhang B, Xu N, et al. Refractory serositis in Gorham-Stout syndrome. Orphanet J Rare Dis. 2022;17(1):152. doi: 10.1186/s13023-022-02307-8

[32] Di H., Zhang B., Xu N., et al. Refractory serositis in Gorham-Stout syndrome // Orphanet J Rare Dis. 2022. Vol. 17, N. 1. P. 152. doi: 10.1186/s13023-022-02307-8

[33] Geeurickx M, Labarque V. A narrative review of the role of sirolimus in the treatment of congenital vascular malformations. J Vasc Surg Venous Lymphat Disord. 2021;9(5):1321–1333. doi: 10.1016/j.jvsv.2021.03.001

[34] Geeurickx M., Labarque V. A narrative review of the role of sirolimus in the treatment of congenital vascular malformations // J Vasc Surg Venous Lymphat Disord. 2021. Vol. 9, N. 5. P. 1321–1333. doi: 10.1016/j.jvsv.2021.03.001

[35] Nadal M, Giraudeau B, Tavernier E, et al. Efficacy and safety of mammalian target of rapamycin inhibitors in vascular anomalies: a systematic review. Acta Derm Venereol. 2016;96(4):448–452. doi: 10.2340/00015555-2300

[36] Nadal M., Giraudeau B., Tavernier E., et al. Efficacy and safety of mammalian target of rapamycin inhibitors in vascular anomalies: a systematic review // Acta Derm Venereol. 2016. Vol. 96, N. 4. P. 448–452. doi: 10.2340/00015555-2300

[37] Ozeki M, Nozawa A, Yasue S, et al. The impact of sirolimus therapy on lesion size, clinical symptoms, and quality of life of patients with lymphatic anomalies. Orphanet J Rare Dis. 2019;14(1):141. doi: 10.1186/s13023-019-1118-1

[38] Ozeki M., Nozawa A., Yasue S., et al. The impact of sirolimus therapy on lesion size, clinical symptoms, and quality of life of patients with lymphatic anomalies // Orphanet J Rare Dis. 2019. Vol. 14, N. 1. P. 141. doi: 10.1186/s13023-019-1118-1

[39] Shameem R, Lacouture M, Wu S. Incidence and risk of rash to mTOR inhibitors in cancer patients – a meta-analysis of randomized controlled trials. Acta Oncol. 2015;54(1):124–132. doi: 10.3109/0284186X.2014.923583

[40] Shameem R., Lacouture M., Wu S. Incidence and risk of rash to mTOR inhibitors in cancer patients – a meta-analysis of randomized controlled trials // Acta Oncol. 2015. Vol. 54, N. 1. P. 124–132. doi: 10.3109/0284186X.2014.923583

[41] Gomez-Fernandez C, Garden BC, Wu S, et al. The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis. Eur J Cancer. 2012;48(3):340–346. doi: 10.1016/j.ejca.2011.11.028

[42] Gomez-Fernandez C., Garden B.C., Wu S., et al. The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis // Eur J Cancer. 2012. Vol. 48, N. 3. P. 340–346. doi: 10.1016/j.ejca.2011.11.028

[43] Kuriyama DK, McElligott SC, Glaser DW, Thompson KS. Treatment of Gorham–Stout disease with zoledronic acid and interferon-α: a case report and literature review. J Pediatr Hematol Oncol. 2010;32(8):579–584. doi: 10.1097/MPH.0b013e3181edb464

[44] Kuriyama D.K., McElligott S.C., Glaser D.W., Thompson K.S. Treatment of Gorham–Stout disease with zoledronic acid and interferon-α: a case report and literature review // J Pediatr Hematol Oncol. 2010. Vol. 32, N. 8. P. 579–584. doi: 10.1097/MPH.0b013e3181edb464

RIGHTS & PERMISSIONS

Eco-Vector